SCHEMBL6284908

SCHEMBL6284908

CN(C)N(Cc1cccc([N+](=O)[O-])c1)C(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYCR1 P32322 1/20 0.49
CYP2D6 P10635 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP1A2 P05177 1/20 0.48
ACHE P22303 1/20 0.47
ALDH1A1 P00352 3/20 0.46
LMNA P02545 3/20 0.46
MAPT P10636 4/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ALOX5 P09917 1/20 0.44
MAOB P27338 2/20 0.44
MAOA P21397 1/20 0.44
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
ATM Q13315 1/20 0.43
NR3C2 P08235 1/20 0.43
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3296353 0.88 PYCR1 (0.51) PYCR1CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL6679985 0.86 CYP2D6 (0.51) PYCR1CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL16107703 0.84 CYP2D6 (0.49) PYCR1CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL399471 0.84 CYP2D6 (0.49) PYCR1CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL6674347 0.83 CYP1A2 (0.54) PYCR1CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL6978108 0.82 CYP2D6 (0.62) PYCR1CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL15498167 0.81 CYP1A2 (0.49) PYCR1CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL30270586 0.81 CYP1A2 (0.52) PYCR1CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL3127049 0.81 ALDH1A1 (0.56) PYCR1CYP2D6CYP2C9CYP2C19CYP1A2
SCHEMBL16706160 0.81 PYCR1 (0.55) PYCR1CYP2D6CYP2C9CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887891-B2 Derivatives of lipoic acid, their preparation, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2005-05-03 US disclosed
US-20040019084-A1 New derivatives of lipoic acid, their preparation, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019084-A1 New derivatives of lipoic acid, their preparation, their use as medicaments and the pharmaceutical compositions containing them NOS1, NOS2, LPO PYCR1 48/4885CYP2D6 621/4885CYP2C9 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.